论文部分内容阅读
多发性硬化症(MS)是1种复杂的以中枢神经系统慢性炎性反应为特征的基因性疾病。其病理学原因在很大程度上归于自身反应性效应T细胞透过血-脑屏障,在中枢神经系统中激活。自身反应性效应T细胞既存在于MS患者血液中,也存在于健康人群的血液中,所以就有其他的调节机制存在来阻止自身反应性效应T细胞引起免疫紊乱。抑制活性的调节T细胞在控制自身抗原反应性T细胞以及介导体内外周血耐受过程中起着非常关键的作用。本文重点讨论Tregs与MS的免疫病理学改变之间的关系,以及成为治疗MS潜在靶标的可能性。
Multiple sclerosis (MS) is a complex genetic disease characterized by chronic inflammatory reactions in the central nervous system. Its pathological cause is largely due to autoreactive T cells that activate through the blood-brain barrier and are activated in the central nervous system. Autoreactive T cells exist both in the blood of MS patients and in the blood of healthy people, so other regulatory mechanisms exist that prevent autoreactive T cells from causing immune disorders. Regulatory T cells that inhibit activity play a crucial role in the regulation of autoantigen-reactive T cells and in the mediation of peripheral blood tolerance in vivo. This article focuses on the relationship between Tregs and immunopathological changes in MS and the potential to become potential targets for the treatment of MS.